Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$189.50 -0.7%	$187.12	$163.63 ▼ $218.66	$336.94B	0.48	6.25 million shs	3.71 million shs
MRK Merck & Co., Inc.	$80.97 -1.7%	$79.22	$73.31 ▼ $129.93	$206.88B	0.39	13.26 million shs	7.73 million shs
NVO Novo Nordisk A/S	$69.05 -1.1%	$69.69	$57.00 ▼ $143.69	$311.75B	0.64	7.25 million shs	4.05 million shs
NVS Novartis	$121.90 -1.5%	$114.67	$96.06 ▼ $124.45	$261.54B	0.59	1.59 million shs	955,240 shs
PFE Pfizer	$25.45 +0.5%	$23.62	$20.92 ▼ $31.54	$143.95B	0.58	41.63 million shs	27.10 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+0.45%	+2.77%	+2.14%	-5.23%	+14.95%
MRK Merck & Co., Inc.	+0.75%	+3.29%	+8.05%	-4.59%	-35.52%
NVO Novo Nordisk A/S	-0.06%	+3.62%	-4.08%	+4.07%	-51.18%
NVS Novartis	+0.63%	+5.00%	+6.12%	+10.20%	+16.31%
PFE Pfizer	+1.16%	+4.24%	+8.00%	+4.22%	-9.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.9069 of 5 stars	3.4	5.0	3.3	3.9	2.8	1.7	1.3
MRK Merck & Co., Inc.	4.9963 of 5 stars	3.2	3.0	5.0	3.9	3.0	2.5	3.8
NVO Novo Nordisk A/S	4.7497 of 5 stars	4.1	5.0	2.5	0.0	2.8	0.0	3.1
NVS Novartis	1.6794 of 5 stars	1.0	3.0	2.5	0.0	2.7	0.0	1.9
PFE Pfizer	4.9753 of 5 stars	3.2	3.0	4.2	4.3	2.8	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.81	Moderate Buy	$211.29	11.50% Upside
MRK Merck & Co., Inc.	2.43	Hold	$109.19	34.85% Upside
NVO Novo Nordisk A/S	2.27	Hold	$112.00	62.20% Upside
NVS Novartis	2.00	Hold	$123.67	1.45% Upside
PFE Pfizer	2.45	Hold	$28.55	12.20% Upside

Current Analyst Ratings Breakdown

Latest NVO, MRK, ABBV, PFE, and NVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$205.00
6/9/2025	ABBV AbbVie	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$204.00
5/29/2025	PFE Pfizer	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold	$28.00 ➝ $25.00
5/21/2025	PFE Pfizer	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $33.00
5/20/2025	MRK Merck & Co., Inc.	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Cautious
5/19/2025	PFE Pfizer	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy	$27.00 ➝ $26.00
5/14/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$210.00 ➝ $205.00
5/14/2025	MRK Merck & Co., Inc.	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$115.00 ➝ $84.00
5/8/2025	ABBV AbbVie	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/30/2025	PFE Pfizer	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform	$22.00 ➝ $23.00
4/30/2025	PFE Pfizer	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral	$29.00 ➝ $27.00

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	5.94	$14.84 per share	12.77	$1.90 per share	99.74
MRK Merck & Co., Inc.	$64.17B	3.17	$9.31 per share	8.70	$18.33 per share	4.42
NVO Novo Nordisk A/S	$42.12B	7.32	$3.86 per share	17.90	$4.66 per share	14.82
NVS Novartis	$50.32B	5.12	$10.54 per share	11.57	$21.59 per share	5.65
PFE Pfizer	$63.63B	2.27	$4.39 per share	5.80	$15.62 per share	1.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.35	80.64	13.56	1.27	7.31%	412.03%	13.11%	7/24/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.87	11.79	8.18	0.85	27.27%	43.23%	17.11%	7/29/2025 (Estimated)
NVO Novo Nordisk A/S	$14.64B	$3.38	20.43	14.82	1.36	34.52%	80.94%	24.23%	8/6/2025 (Estimated)
NVS Novartis	$11.94B	$6.40	19.05	13.84	1.70	24.70%	39.44%	16.43%	7/17/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	18.44	8.40	0.92	12.62%	20.33%	8.53%	8/5/2025 (Estimated)

Latest NVO, MRK, ABBV, PFE, and NVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/29/2025	Q2 2025	MRK Merck & Co., Inc.	$2.03	N/A	N/A	N/A	$15.92 billion	N/A
7/24/2025	Q2 2025	ABBV AbbVie	$3.24	N/A	N/A	N/A	$14.93 billion	N/A
7/17/2025	Q2 2025	NVS Novartis	$2.37	N/A	N/A	N/A	$13.94 billion	N/A
5/7/2025	Q1 2025	NVO Novo Nordisk A/S	$0.92	$0.92	N/A	$0.92	N/A	$11.87 billion
4/29/2025	Q1 2025	NVS Novartis	$2.12	$2.28	+$0.16	$1.83	$12.92 billion	$13.23 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/25/2025	Q1 2025	ABBV AbbVie	$2.40	$2.46	+$0.06	$0.72	$12.91 billion	$13.34 billion
4/24/2025	Q1 2025	MRK Merck & Co., Inc.	$2.16	$2.22	+$0.06	$2.01	$15.59 billion	$15.53 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.46%	N/A	279.15%	53 Years
MRK Merck & Co., Inc.	$3.24	4.00%	N/A	47.16%	14 Years
NVO Novo Nordisk A/S	$1.64	2.38%	N/A	48.52%	N/A
NVS Novartis	$2.60	2.13%	N/A	40.63%	N/A
PFE Pfizer	$1.72	6.76%	N/A	124.64%	16 Years

Latest NVO, MRK, ABBV, PFE, and NVS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%	7/15/2025	7/15/2025	8/15/2025
5/27/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4.18%	6/16/2025	6/16/2025	7/8/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.76	0.64
MRK Merck & Co., Inc.	0.69	1.41	1.16
NVO Novo Nordisk A/S	0.70	0.74	0.56
NVS Novartis	0.56	0.79	0.61
PFE Pfizer	0.64	1.26	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
MRK Merck & Co., Inc.	76.07%
NVO Novo Nordisk A/S	11.54%
NVS Novartis	13.12%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.25%
MRK Merck & Co., Inc.	0.13%
NVO Novo Nordisk A/S	0.07%
NVS Novartis	0.01%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.76 billion	Optionable
MRK Merck & Co., Inc.	75,000	2.51 billion	2.51 billion	Optionable
NVO Novo Nordisk A/S	77,349	4.47 billion	4.46 billion	Optionable
NVS Novartis	75,883	2.11 billion	2.11 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

NVO, MRK, ABBV, PFE, and NVS Headlines

Recent News About These Companies

Stocks At All-Time Highs – Grab Your Gains and Buy These 7% Dividend Gems

July 3 at 4:33 PM | 247wallst.com

Pfizer’s New Pneumococcal Vaccine Study: A Potential Game Changer for Children’s Health

July 3 at 12:20 PM | tipranks.com

Pfizer’s ARV-471: A Promising New Hope for Advanced Breast Cancer

July 3 at 12:20 PM | tipranks.com

Pfizer: Options Activity Speaks Bullish

July 3 at 10:36 AM | seekingalpha.com

Pfizer: Options Activity Speaks Bullish

July 3 at 10:02 AM | seekingalpha.com

Pfizer Trades Above 50-Day Average for a Month: Time to Buy?

July 3 at 9:51 AM | zacks.com

D.A. Davidson & CO. Has $49.12 Million Stock Position in Pfizer Inc. (NYSE:PFE)

July 3 at 8:46 AM | marketbeat.com

Mutual Advisors LLC Buys 20,583 Shares of Pfizer Inc. (NYSE:PFE)

July 3 at 8:25 AM | marketbeat.com

Teacher Retirement System of Texas Buys 361,603 Shares of Pfizer Inc. (NYSE:PFE)

July 3 at 7:29 AM | marketbeat.com

First Horizon Advisors Inc. Has $20.91 Million Stock Position in Pfizer Inc. (NYSE:PFE)

July 3 at 7:08 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Purchased by WCM Investment Management LLC

July 3 at 5:38 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Bought by DAVENPORT & Co LLC

July 3 at 5:18 AM | marketbeat.com

Is Pfizer Stock a Yield Trap?

July 3 at 4:28 AM | fool.com

Pfizer (PFE) Outperforms Broader Market: What You Need to Know

July 2 at 6:46 PM | zacks.com

Huge Unusual Volume In Pfizer Put Options Signals Investors Bullish Outlook

July 2 at 3:48 PM | talkmarkets.com

Lawmakers Investigate Whether Pfizer Delayed COVID-19 Vaccine Results For Political Reasons

July 2 at 2:06 PM | benzinga.com

Republicans subpoena former Pfizer exec over timing of COVID vaccine clinical tests

July 2 at 1:25 PM | msn.com

Pfizer’s New Study on Mevrometostat and Enzalutamide: Potential Game-Changer in Prostate Cancer Treatment?

July 2 at 12:41 PM | tipranks.com

Pfizer’s Phase 3 RSV Vaccine Study: A Potential Game-Changer for Maternal and Infant Health

July 2 at 12:41 PM | tipranks.com

Kanawha Capital Management LLC Purchases 24,026 Shares of Pfizer Inc. (NYSE:PFE)

July 2 at 9:08 AM | marketbeat.com

House Subpoenas Ex-Pfizer Scientist in Election Meddling Probe

July 2 at 8:25 AM | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
RKLB Breakout Fails Near Highs: Should Investors Be Concerned?
By Ryan Hasson | June 11, 2025
View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?
With Novo Nordisk's CEO Out, Wall Street Wants an American Leader
By Leo Miller | June 7, 2025
View With Novo Nordisk's CEO Out, Wall Street Wants an American Leader

NVO, MRK, ABBV, PFE, and NVS Company Descriptions

AbbVie NYSE:ABBV

$189.50 -1.25 (-0.66%)

Closing price 03:58 PM Eastern

Extended Trading

$188.90 -0.60 (-0.32%)

As of 04:58 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Merck & Co., Inc. NYSE:MRK

$80.97 -1.42 (-1.72%)

Closing price 03:59 PM Eastern

Extended Trading

$80.99 +0.02 (+0.02%)

As of 04:58 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novo Nordisk A/S NYSE:NVO

$69.05 -0.77 (-1.10%)

Closing price 03:58 PM Eastern

Extended Trading

$69.12 +0.08 (+0.11%)

As of 04:59 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novartis NYSE:NVS

$121.90 -1.91 (-1.54%)

Closing price 03:30 PM Eastern

Extended Trading

$123.50 +1.60 (+1.32%)

As of 04:04 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Pfizer NYSE:PFE

$25.44 +0.13 (+0.49%)

Closing price 03:59 PM Eastern

Extended Trading

$25.42 -0.03 (-0.11%)

As of 05:00 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NVO, MRK, ABBV, PFE, and NVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NVO, MRK, ABBV, PFE, and NVS Earnings

Compare Dividends

Latest NVO, MRK, ABBV, PFE, and NVS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NVO, MRK, ABBV, PFE, and NVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NVO, MRK, ABBV, PFE, and NVS Company Descriptions

AbbVie NYSE:ABBV

Merck & Co., Inc. NYSE:MRK

Novo Nordisk A/S NYSE:NVO

Novartis NYSE:NVS

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools